Results 41 to 50 of about 448,532 (222)

Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study [PDF]

open access: yes, 2012
Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease.
Bachmann, Malte   +11 more
core   +1 more source

Weakly-supervised positional contrastive learning: application to cirrhosis classification [PDF]

open access: yesarXiv, 2023
Large medical imaging datasets can be cheaply and quickly annotated with low-confidence, weak labels (e.g., radiological scores). Access to high-confidence labels, such as histology-based diagnoses, is rare and costly. Pretraining strategies, like contrastive learning (CL) methods, can leverage unlabeled or weakly-annotated datasets.
arxiv  

Liver cirrhosis-epidemiological and Clinical Aspects [PDF]

open access: yes, 2008
Liver cirrhosis is the end-stage of many different chronic liver diseases. Limited data exists on the epidemiology, natural history and complications of liver cirrhosis such as esophageal varices and malignancies in the Nordic countries after the ...
Gunnarsdóttir, Steingerður Anna
core  

To identify and examine the different causes of liver disease in Sri Lanka [PDF]

open access: yes, 2017
© 2017 The Authors. Published by International Journal of Science and Research. This is an open access article available under a Creative Commons licence.
Aslam, Fahim, Kulasena, Hashan
core   +1 more source

Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization

open access: yesBMC Gastroenterology
Background Skeletal muscle index (SMI) is a commonly used research method for evaluating muscle mass.However, its impact on post-embolization syndrome(PES) of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE ...
Xiaojuan Wang   +9 more
doaj   +1 more source

The burden of clostridium difficile infection in patients with liver cirrhosis [PDF]

open access: yes, 2019
Clostridium Difficile Infection (CDI) has registered a dramatically increasing incidence in the general population over the past decades. Nowadays, Clostridium Difficile is the leading cause of hospital-acquired diarrhea in Europe and North America ...
Dumitru, Andrada   +5 more
core   +1 more source

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]

open access: yes, 2017
Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero   +11 more
core   +1 more source

Enhancement Pattern Mapping for Detection of Hepatocellular Carcinoma in Patients with Cirrhosis [PDF]

open access: yesarXiv, 2023
Background and Aims: Limited methods exist to accurately characterize risk of malignant progression of liver lesions in patients undergoing surveillance for hepatocellular carcinoma (HCC). Enhancement pattern mapping (EPM) measures voxel-based root mean square deviation (RMSD) and improves the contrast-to-noise ratio (CNR) of liver lesions on standard ...
arxiv  

The risk of bleeding and encephalopathy in surgical patients with liver cirrhosis [PDF]

open access: yes, 2019
Liver cirrhosis is a disease with an increasing incidence. Surgical procedures in patients with cirrhosis are also increasing, due to a longer life expectancy in these patients and also to the improvement of therapeutic and diagnostic resources ...
Bacalbașa, Nicolae   +9 more
core   +1 more source

Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis [PDF]

open access: yes, 2018
Background. The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. Aim.
Aprile, Francesca   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy